2016 ASCO Annual Meeting - ASCO


Powered by SmugMug Log In
Paul E. Goss, MD, PhD, presenting LBA1, A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer duringPlenary Session including Science of Oncology Award and Lecture

Paul E. Goss, MD, PhD, presenting LBA1, A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer duringPlenary Session including Science of Oncology Award and Lecture

Chicago, IL - 2016 ASCO Annual Meeting - Paul E. Goss, MD, PhD, presenting LBA1, A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer during Plenary Session including Science of Oncology Award and Lecture at the American Society of Clinical Oncology (ASCO) Annual Meeting here today, Sunday, June 5, 2016. Over 30,000 physicians, researchers, and healthcare professionals from over 100 countries are attending the 52nd Annual Meeting which is being held at the McCormick Place convention center. The Annual Meeting highlights the latest findings in all major areas of oncology from basic through clinical and epidemiological studies. Photo by © ASCO/Brian Powers 2016 Technical Questions: todd@medmeetingimages.com; ASCO Contact: photos@asco.org